Dynamic immune signatures as biomarkers for irAEs

Johnson, 2022, Immune-checkpoint inhibitors: long-term implications of toxicity, Nat. Rev. Clin. Oncol., 19, 254, 10.1038/s41571-022-00600-w

Jing, 2022, Harnessing big data to characterize immune-related adverse events, Nat. Rev. Clin. Oncol., 19, 269, 10.1038/s41571-021-00597-8

Jing, 2020, Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy, Nat. Commun., 11, 4946, 10.1038/s41467-020-18742-9

Jing, 2021, Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy, J. Natl. Cancer Inst., 113, 1396, 10.1093/jnci/djab035

Nuñez, 2023, Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors, Med, 4, 113, 10.1016/j.medj.2022.12.007

Groha, 2022, Germline variants associated with toxicity to immune checkpoint blockade, Nat. Med., 28, 2584, 10.1038/s41591-022-02094-6

Taylor, 2022, IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma, Nat. Med., 28, 2592, 10.1038/s41591-022-02095-5

Bukhari, 2023, Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors, Cell Reports Med., 4, 10.1016/j.xcrm.2022.100868

Lesterhuis, 2017, Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity, Nat. Rev. Drug Discov., 16, 264, 10.1038/nrd.2016.233